The Pointy End of the TGA (PI) Reformatting Transition Period

TGA's new Product Information (PI) Form: If you need support to meet the 31 December 2020 deadline, we’re here to help.

By now, we should all be very familiar with the new Form for providing  TGA Product Information (PI) for Australia Each time you make a change to a PI, be it safety-related or otherwise, you’re required to provide the updated PI to TGA in the new format.

The looming deadline for marketed product PIs to be in the new format is  31 December 2020 . As we are already in mid-March, that’s not very far away. However, more than two thirds of the way through the transition period, a review of a random sample of PIs indicates that approximately  45% of products on the ARTG are still in the old format!

TGA are trying to help Sponsors meet the deadline. To encourage submissions, they have introduced a fee exemption, until the end of the year, for applications where the only change is to reformat the PI and no other editorial changes are made.

What can you do to make the process easier?

  1. Establishing a robust template is extremely important. Although the TGA have provided a bookmarked template, it can be significantly upgraded to include mandatory and standard TGA statements, as well as standardised company preferred text and instructions for the reformatting party.
  2. Documenting PI reformatting decisions and implementing them consistently across the organisation is also key to improving efficiency. Reformatting is not an exact science – variability abounds.

If you need support to meet the 31 December 2020 deadline, we’re here to help.

Our team of regulatory experts and medical writers can efficiently manage your PI reformatting as an outsourced project, relieving the burden on you and your team. Take the stress out of your PI reformatting project today by contacting us.

Contact us today for an initial consultation and learn how we can add value to your business.

More recent articles

  • Choosing the Right Regulatory Affairs Consultant

    Choosing the Right Regulatory Affairs Consultant

    Whether you are part of an established team, a start-up, an SME, or a founder, navigating the stringent requirements of the Medical Technology, Biotechnology, and Pharmaceutical (MTP) sectors can be complex and challenging. This is where partnering with the right Regulatory Affairs Consultant becomes invaluable. Understanding the Role of a Regulatory Affairs Consultant A regulatory…

  • Cell and Gene Therapies Regulation

    Cell and Gene Therapies Regulation

    Navigating the Regulation of Cell and Gene Therapies in Australia and New Zealand Globally, cell and gene therapies are revolutionising modern medicine, offering groundbreaking treatments for life-threatening conditions including cancer, genetic disorders and rare diseases. However, despite the pace of scientific innovation, regulatory frameworks in many countries, including Australia and New Zealand, have struggled to…

  • Medical Device Registration in Australia

    Medical Device Registration in Australia

    Key considerations in navigating the regulatory process to register a medical device in Australia. Registering a medical device in Australia is a complex but crucial process that ensures the safety and performance of devices entering the healthcare market. Navigating the regulatory requirements of the Therapeutic Goods Administration (TGA) can be daunting, particularly for new manufacturers…